Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
ALPHARETTA, Ga., Aug. 08, 2017 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that it will participate in three upcoming events.
Clearside will host a Key Opinion Leader (“KOL”) luncheon event on Thursday, August 10, 2017 in Boston, MA. The invited speaker for this event is Dr. David M. Brown, a prominent Houston, TX-based retinal specialist and thought leader on the research and treatment of retinal vein occlusion (“RVO”), diabetic macular edema (“DME”) and age-related macular degeneration (“AMD”). The KOL lunch event will not be webcast.
Clearside’s Chief Executive Officer and President, Daniel H. White, will participate in a panel discussion on retinal drug delivery at the Ophthalmology Innovation Summit (“OIS”) to be held Thursday, August 10, 2017 in conjunction with the 35th Annual Scientific Meeting of the American Society of Retinal Specialists (“ASRS”) in Boston, MA. The panel discussion at OIS@ASRS will not be webcast.
Clearside management will also participate in the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017 at the Le Parker Meridien Hotel in New York, NY. Mr. White will participate in a lunch panel entitled, “New Technologies in Drug Delivery,” at 11:30 a.m. ET and will present at 2:30 p.m. ET. A live webcast of the presentation can be accessed on Clearside’s website at www.clearsidebio.com under the “Events & Presentations” tab in the “Investor Relations” section. Following the conference, the presentation webcast will be archived on the website for 30 days.
About Clearside
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and preclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, RVO, DME and AMD. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Contacts: Stephen Kilmer Investor Relations (678) 270-3631 [email protected] Charles Deignan Chief Financial Officer (678) 270-4005 [email protected]
